Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Human Resources | May 03, 2016 | May 06, 2016 |
| MANNKIND CORPMNKD · Entity 4792 | Chief People & Workpl Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2016 · Filed May 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,671 |
Reported balance
After 2016-05-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-05-03 · Grant · Acquired 2,046 · Balance 25,671 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.35 · Expires 2026-05-03 | Direct | 17,422 |
Reported balance
After 2016-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-05-03 · Grant · Acquired 17,422 · Balance 17,422 F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 593.142 |
Reported balance
Holding disclosure · report date 2016-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 593.142 F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,123,950 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 93,790 · Balance 1,123,950 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,090,298 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 33,652 · Balance 1,090,298 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,082,045 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 8,253 · Balance 1,082,045 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,070,473 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 11,572 · Balance 1,070,473 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,058,142 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 12,331 · Balance 1,058,142 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 93,790 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionPerformance Restricted Stock Unit · Derivative | 93,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · derivative · entry 6 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 93,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,331 | $4.09 | $50,433.79 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 5 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,058,142 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 11,572 | $4.09 | $47,329.48 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 4 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,473 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 8,253 | $4.09 | $33,754.77 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,082,045 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 33,652 | $4.09 | $137,636.68 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,298 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 93,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,123,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F2 · balance_after: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:49 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 33,898 | $2.95 | $99,999.10 |
DisclosureSEC source: 0001193125-26-237429 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,026,122 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026. Read SEC document |
| May 11, 2026 Filed May 14, 2026 00:30 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 8,073 | $3.52 | $28,416.96 |
DisclosureSEC source: 0001193125-26-222312 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,224 F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 217,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001193125-26-124722 · ownership.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,000 Underlying: Common Stock, $0.01 Par Value · 217,000 shares Expires 2036-03-23 F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 221,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124722 · ownership.xml · derivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,000 Underlying: Common Stock, $0.01 Par Value · 221,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001193125-26-086376 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,297 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on March 1, 2026. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 28,143 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001193125-26-086376 · ownership.xml · derivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,143 Underlying: Stock Options · 28,143 shares Expires 2027-05-25 F3 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-26-086376 · ownership.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Stock Options · 20,000 shares Expires 2027-02-15 F2 · kind: On February 16, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 47,006 | $6.33 | $297,547.98 |
DisclosureSEC source: 0001193125-26-009297 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 985,007 F1 · kind: Transaction occured pursuant to Rule 10B5-1 Plan established June 17, 2025. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:39 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 47,000 | $5.34 | $250,980.00 |
DisclosureSEC source: 0001193125-25-206517 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,032,013 F1 · kind: Transaction occured pursuant to Rule 10B5-1 Plan established June 17, 2025. F2 · price: The weighted average sales price of the reported transaction was $5.34 based on a range of prices between $5.33 and $5.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 12,755 | $3.92 | $49,999.60 |
DisclosureSEC source: 0000950170-25-104395 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,079,013 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on August 5, 2025. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 00:46 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 28,057 | $3.85 | $108,019.45 |
DisclosureSEC source: 0000950170-25-096738 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066,258 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 3,888 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| May 19, 2025 Filed May 21, 2025 01:47 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 6,147 | $4.37 | $26,862.39 |
DisclosureSEC source: 0000950170-25-075540 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,427 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:33 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073080 · ownership.xml · derivative · entry 5 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, $0.01 Par Value · 145,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F6 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F6 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:33 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 4 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,096,574 F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · balance_after: Includes 1,558 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:33 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 8,051 | $4.56 | $36,712.56 |
DisclosureSEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,016 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:33 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 88,724 | $4.56 | $404,581.44 |
DisclosureSEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 984,067 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2025 Filed May 16, 2025 01:33 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 105,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073080 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072,791 F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 02:30 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 55,000 | $7.34 | $403,700.00 |
DisclosureSEC source: 0000950170-24-124349 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 967,191 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 01:11 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 25,000 | $6.26 | $156,500.00 |
DisclosureSEC source: 0000950170-24-103683 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,022,191 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024. F2 · price: The weighted average sales price of the reported transaction was $6.26 based on a range of prices between $6.19 and $6.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 35,000 | $6.32 | $221,200.00 |
DisclosureSEC source: 0000950170-24-102517 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,047,191 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024. F2 · kind: The weighted average sales price for the transaction reported was $6.32 based on a range of prices between $6.25 and $6.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 45,000 | $6.33 | $284,850.00 |
DisclosureSEC source: 0000950170-24-102517 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,082,191 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established May 31, 2024. Read SEC document |
| August 27, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 20,779 | $5.38 | $111,791.02 |
DisclosureSEC source: 0000950170-24-102042 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,127,191 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 11,657 | $5.83 | $67,960.31 |
DisclosureSEC source: 0000950170-24-084406 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,147,970 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 4,689 | $3.09 | $14,489.01 |
DisclosureSEC source: 0000950170-24-084406 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,159,627 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 6,130 | $4.59 | $28,136.70 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,938 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 62,056 | $4.59 | $284,837.04 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,068 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 77,420 | $4.59 | $355,357.80 |
DisclosureSEC source: 0000950170-24-063263 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223,124 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062070 · ownership.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062070 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,704 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 8,028 | $4.32 | $34,680.96 |
DisclosureSEC source: 0000950170-24-059960 · ownership.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016,704 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,732 F3 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 1,006 | $3.09 | $3,108.54 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,009,442 F2 · kind: Includes 1006 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 20,328 | $4.72 | $95,948.16 |
DisclosureSEC source: 0001209191-23-047551 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,004,424 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2023 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 4,012 | $3.46 | $13,881.52 |
DisclosureSEC source: 0001209191-24-002744 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,436 F1 · kind: Includes 4012 shares of common stock purchased under the Company's Employee Stock Purchase Plan on June 30, 2023 in an exempt transaction. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032731 · doc4.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock, $.01 Par Value · 113,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 92,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032731 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,752 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 279,998 | $4.79 | $1,341,190.42 |
DisclosureSEC source: 0001209191-23-032033 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 932,752 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 400,000 | $4.79 | $1,916,000.00 |
DisclosureSEC source: 0001209191-23-032033 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,212,750 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 5,941 | $4.56 | $27,090.96 |
DisclosureSEC source: 0001209191-23-031287 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,750 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock,$.01 par value | 10,000 | $4.23 | $42,300.00 |
DisclosureSEC source: 0001209191-23-029517 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,691 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 7,781 | $4.40 | $34,236.40 |
DisclosureSEC source: 0001209191-23-029236 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,691 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 14,178 | $3.73 | $52,883.94 |
DisclosureSEC source: 0001209191-22-047942 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,472 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 4,581 | $2.93 | $13,422.33 |
DisclosureSEC source: 0001209191-22-043572 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,650 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:01 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 4,581 | $2.93 | $13,422.33 |
DisclosureSEC source: 0001209191-22-047429 · doc4a.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,650 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.